alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › early

early

4 studies tagged early, dated 2015-01-01 to 2024-06-28. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease 2024-06-28
  2. Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease 2022-09-27
  3. Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease 2015-10-01

Studies

4 studies carry this tag.

Date range

2015 to 2024

Top journals

  • Alzheimer's & dementia : the journal of the Alzheimer's Association 1
  • CPT: pharmacometrics & systems pharmacology 1
  • JAMA neurology 1
  • Journal of Parkinson's disease 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 55 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2024-06-28 Biomarkers

    Models integrating pTau217R outperformed Aβ42/Aβ40 alone, predicting amyloid levels up to 89.1 CL.

  2. Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. CPT: pharmacometrics & systems pharmacology 2022-09-27 Biomarkers

    Lecanemab is a humanized immunoglobulin G1 monoclonal antibody that selectively binds to soluble Aβ aggregate species, while demonstrating low affinity for Aβ monomer.

  3. Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease

    ✓ Peer-reviewed alzhub usefulness score 64 out of 100. JAMA neurology 2015-10-01 Biomarkers

    Among the 128 study participants, the 104 patients with early PD had a different CSF pattern compared with the 13 patients with progressive supranuclear palsy (baseline area under the receiver operating characteristic curve, 0.87; P < .0001) and the 30 control participants (baseline area under the receiver operating characteristic curve, 0.69; P = .0021).

  4. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Journal of Parkinson's disease 2015-01-01 Biomarkers

    The association between reduced CSF α-synuclein concentrations and cognition suggests that α-synuclein pathology contributes to early cognitive impairment in PD, in particular to executive-attentional dysfunction.

All topic tags with their study counts